Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 10, 2025AntioxidantsOpen Access

Biomarker-Driven Optimization of Saponin Therapy in MASLD: From Mouse Models to Human Liver Organoids

View Full Paper
Ask AI
Bookmark
Share

Authors

HKHye Young KimJOJu‐Hee OhHKHyunsung Kim

Discussion

Loading...

Member takes

Overview

Observational analysis demonstrates saponin's impact on liver inflammation in MASLD models, suggesting HAMP1 as a biomarker.

Key Points

  • Saponin treatment reduced NAFLD Activity Score, indicating improved liver function in certain diet models.
  • RNA sequencing revealed significant changes in metabolic processes linked to lipid and triglyceride levels.
  • Assessment of liver organoids verified saponin's therapeutic effects, especially in red ginseng diets.
  • Increased HAMP1 expression suggests it may serve as an exploratory biomarker for saponin efficacy.

Cite This Study

Kim et al. (2025) studied this question.

synapsesocial.com/papers/68c1bb7054b1d3bfb60ed758https://doi.org/10.3390/antiox14080943
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Sanzi Sijun Formula Alleviates Lipotoxic Liver Injury in Metabolic Dysfunction-Associated Steatotic Liver Disease via AMPK/SIRT1 Signaling Pathway2026
  2. 2Metabolic Dysfunction-Associated Steatotic Liver Disease in a Dish: Human Precision-Cut Liver Slices as a Platform for Drug Screening and Interventions2024 · 19 citations
  3. 3Research progress on the mechanistic pathways and biomarkers of therapeutic drugs for metabolic-associated steatotic liver disease2026 · 1 citations
  4. 4Targeting lanosterol synthase alleviates MASLD by promoting fatty acid catabolism2026
  5. 5Lipid Metabolic Reprogramming and Bioactive Lipid Signaling in MASLD: Molecular Mechanisms, Pathogenesis and Therapeutic Opportunities2026